

RaÃ³l J Andrade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3144786/publications.pdf>

Version: 2024-02-01

190
papers

13,652
citations

32410

55
h-index

27587

110
g-index

210
all docs

210
docs citations

210
times ranked

9989
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521. | 0.6 | 847 |
| 2 | Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005, 128, 636-641. | 0.6 | 699 |
| 3 | EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019, 70, 1222-1261. | 1.8 | 629 |
| 4 | Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521. | 0.6 | 595 |
| 5 | Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347. | 0.6 | 412 |
| 6 | Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58. | 18.1 | 409 |
| 7 | Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut</i> , 2017, 66, 1154-1164. | 6.1 | 370 |
| 8 | Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460. | 0.6 | 361 |
| 9 | Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <i>Gastroenterology</i> , 2019, 156, 2230-2241.e11. | 0.6 | 346 |
| 10 | Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514. | 1.8 | 319 |
| 11 | The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939. | 3.6 | 279 |
| 12 | Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588. | 3.6 | 267 |
| 13 | Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009. | 3.6 | 266 |
| 14 | Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5. | 0.6 | 248 |
| 15 | HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005, 41, 779-789. | 3.6 | 245 |
| 16 | Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001, 33, 123-130. | 3.6 | 240 |
| 17 | Glutathione <i>S</i> -transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596. | 3.6 | 181 |
| 18 | Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 48, 721-727. | 1.8 | 175 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089. | 0.6 | 174 |
| 20 | Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019, 69, 760-773. | 3.6 | 166 |
| 21 | Causality assessment methods in drug induced liver injury: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 55, 683-691. | 1.8 | 164 |
| 22 | Hepatic safety of antibiotics used in primary care. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1431-1446. | 1.3 | 154 |
| 23 | Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856. | 3.6 | 143 |
| 24 | Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase. <i>Drug Safety</i> , 2010, 33, 503-522. | 1.4 | 142 |
| 25 | Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708. | 3.6 | 136 |
| 26 | HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612. | 3.6 | 134 |
| 27 | Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. <i>World Journal of Gastroenterology</i> , 2007, 13, 329. | 1.4 | 134 |
| 28 | Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407. | 1.9 | 125 |
| 29 | Scientific opinion on the safety of green tea catechins. <i>EFSA Journal</i> , 2018, 16, e05239. | 0.9 | 118 |
| 30 | Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542. | 1.8 | 115 |
| 31 | Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016, 17, 537. | 1.8 | 114 |
| 32 | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <i>World Journal of Hepatology</i> , 2014, 6, 160. | 0.8 | 105 |
| 33 | Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5. | 2.4 | 104 |
| 34 | Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312. | 3.6 | 97 |
| 35 | A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2. | 0.6 | 97 |
| 36 | Trovafloxacin-Induced Acute Hepatitis. <i>Clinical Infectious Diseases</i> , 2000, 30, 400-401. | 2.9 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487. | 0.6 | 90 |
| 38 | Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 286-292. | 1.1 | 86 |
| 39 | Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. <i>Gastroenterology</i> , 2019, 157, 552-568. | 0.6 | 85 |
| 40 | Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502. | 2.4 | 83 |
| 41 | HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. <i>PLoS ONE</i> , 2013, 8, e68111. | 1.1 | 81 |
| 42 | Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4. | 0.6 | 76 |
| 43 | Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 249-262. | 1.0 | 75 |
| 44 | Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41. | 3.7 | 75 |
| 45 | Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 435-440. | 0.8 | 72 |
| 46 | Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114. | 1.8 | 72 |
| 47 | Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97. | 1.8 | 72 |
| 48 | Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 329-344. | 1.0 | 70 |
| 49 | Pharmacogenomics in Drug Induced Liver Injury. <i>Current Drug Metabolism</i> , 2009, 10, 956-970. | 0.7 | 70 |
| 50 | The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270. | 1.9 | 70 |
| 51 | Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714. | 1.8 | 69 |
| 52 | Assessment of drug-induced liver injury in clinical practice. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 141-158. | 1.0 | 66 |
| 53 | Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. <i>Journal of Hepatology</i> , 2021, 75, 935-959. | 1.8 | 66 |
| 54 | Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021, 10, 390. | 2.2 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016, 17, 313. | 1.8 | 63 |
| 56 | Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25. | 1.8 | 59 |
| 57 | Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253. | 2.3 | 58 |
| 58 | Acute liver injury associated with the use of ebrotidine, a new H ₂ -receptor antagonist. <i>Journal of Hepatology</i> , 1999, 31, 641-646. | 1.8 | 55 |
| 59 | Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267. | 1.6 | 52 |
| 60 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036. | 2.3 | 52 |
| 61 | A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31. | 3.6 | 52 |
| 62 | Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. <i>Hepatology</i> , 2008, 47, 810-816. | 3.6 | 51 |
| 63 | Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 817-828. | 1.5 | 48 |
| 64 | Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714. | 1.0 | 47 |
| 65 | The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482. | 1.9 | 47 |
| 66 | Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890. | 0.8 | 45 |
| 67 | Metformin-Induced Hepatotoxicity. <i>Diabetes Care</i> , 2012, 35, e21-e21. | 4.3 | 45 |
| 68 | Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 862-874. | 3.7 | 42 |
| 69 | HLA-C and KIR Genes in Hepatitis C Virus Infection. <i>Human Immunology</i> , 2005, 66, 1106-1109. | 1.2 | 41 |
| 70 | Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016, 36, 302-310. | 1.9 | 39 |
| 71 | Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2577-2579. | 1.1 | 38 |
| 72 | Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2013, 33, 1378-1385. | 1.9 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The pro-/anti-inflammatory effects of different fatty acids on visceral adipocytes are partially mediated by GPR120. <i>European Journal of Nutrition</i> , 2017, 56, 1743-1752. | 1.8 | 35 |
| 74 | Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222. | 0.3 | 34 |
| 75 | Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1080-1087. | 0.9 | 34 |
| 76 | Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557. | 1.8 | 34 |
| 77 | Letters to the Editor. <i>Journal of Hepatology</i> , 2000, 32, 174. | 1.8 | 33 |
| 78 | Drug-Induced Liver Injury: Expanding Our Knowledge by Enlarging Population Analysis With Prospective and Scoring Causality Assessment. <i>Gastroenterology</i> , 2015, 148, 1271-1273. | 0.6 | 33 |
| 79 | Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040. | 1.8 | 33 |
| 80 | Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. <i>Journal of Hepatology</i> , 1995, 22, 189-196. | 1.8 | 32 |
| 81 | Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials. <i>Drug Safety</i> , 2014, 37, 19-31. | 1.4 | 32 |
| 82 | Systematic review: ibuprofen-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 603-611. | 1.9 | 32 |
| 83 | Drug-Induced Liver Injury Due to Antimicrobials, Central Nervous System Agents, and Nonsteroidal Anti-Inflammatory Drugs. <i>Seminars in Liver Disease</i> , 2014, 34, 145-161. | 1.8 | 31 |
| 84 | Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015, 62, 751-752. | 1.8 | 31 |
| 85 | Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , 2016, 4, 333-338. | 1.6 | 31 |
| 86 | Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804. | 1.0 | 31 |
| 87 | Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135. | 2.3 | 31 |
| 88 | Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 71-76. | 0.8 | 30 |
| 89 | Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016, 39, 925-943. | 1.4 | 30 |
| 90 | Chronic liver injury induced by drugs and toxins. <i>Journal of Digestive Diseases</i> , 2018, 19, 514-521. | 0.7 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020, 40, 6-17. | 1.9 | 30 |
| 92 | Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837. | 1.6 | 29 |
| 93 | Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404. | 3.1 | 29 |
| 94 | Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348. | 3.1 | 29 |
| 95 | A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017, 12, e0173914. | 1.1 | 28 |
| 96 | Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-239. | 0.6 | 27 |
| 97 | Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3685-3726. | 5.7 | 27 |
| 98 | Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. <i>Current Drug Safety</i> , 2007, 2, 97-112. | 0.3 | 26 |
| 99 | Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute <i>Mycoplasma pneumoniae</i> infection. <i>Clinical Therapeutics</i> , 2009, 31, 1014-1019. | 1.1 | 26 |
| 100 | Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475. | 1.0 | 26 |
| 101 | Benzylpenicillin-Induced Prolonged Cholestasis. <i>Annals of Pharmacotherapy</i> , 2001, 35, 783-784. | 0.9 | 25 |
| 102 | Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1611-1618. | 1.4 | 25 |
| 103 | Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , 2017, 37, 132-140. | 1.9 | 25 |
| 104 | Drug, Herb, and Dietary Supplement Hepatotoxicity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1488. | 1.8 | 24 |
| 105 | Sertraline Hepatotoxicity: Report of a Case and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1806-1807. | 1.1 | 23 |
| 106 | Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. <i>Journal of Hepatology</i> , 2021, 75, 333-341. | 1.8 | 23 |
| 107 | Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 153-169. | 1.5 | 22 |
| 108 | Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2150-2157. | 0.2 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422. | 0.7 | 21 |
| 110 | When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). <i>Clinical Liver Disease</i> , 2019, 13, 51-57. | 1.0 | 21 |
| 111 | Genetic Predisposition to Drug-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2020, 24, 11-23. | 1.0 | 21 |
| 112 | Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e548-e563. | 2.4 | 21 |
| 113 | Long-term sequelae of drug-induced liver injury. <i>Journal of Hepatology</i> , 2022, 76, 435-445. | 1.8 | 21 |
| 114 | Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97. | 1.8 | 21 |
| 115 | Norfloxacin-Induced Cholestatic Jaundice. <i>American Journal of Gastroenterology</i> , 1998, 93, 2309-2311. | 0.2 | 20 |
| 116 | Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019, 39, 381-394. | 1.8 | 20 |
| 117 | Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 929-935. | 1.9 | 19 |
| 118 | Chronic Hepatitis C, Ibuprofen, and Liver Damage. <i>American Journal of Gastroenterology</i> , 2002, 97, 1854-1855. | 0.2 | 19 |
| 119 | Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1540-1541. | 0.9 | 19 |
| 120 | Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165. | 1.4 | 19 |
| 121 | Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. <i>PLoS ONE</i> , 2014, 9, e94675. | 1.1 | 19 |
| 122 | Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 261-276. | 1.3 | 18 |
| 123 | High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294. | 2.4 | 18 |
| 124 | Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 5244-6. | 1.4 | 18 |
| 125 | N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, . | 1.6 | 18 |
| 126 | Severe idiosyncratic acute hepatic injury caused by paracetamol. <i>Journal of Hepatology</i> , 1998, 28, 1078. | 1.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1236-1241. | 0.5 | 17 |
| 128 | “Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge” Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 589-593. | 1.5 | 17 |
| 129 | The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 59-63. | 0.8 | 16 |
| 130 | Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2501-2503. | 1.1 | 16 |
| 131 | Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158. | 2.3 | 16 |
| 132 | Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1416-1419. | 1.1 | 15 |
| 133 | Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948. | 1.8 | 15 |
| 134 | Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. <i>Drug Safety</i> , 2021, 44, 619-634. | 1.4 | 15 |
| 135 | Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1604-1612. | 2.3 | 15 |
| 136 | Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. <i>Gastroenterology Report</i> , 2022, 10, goac014. | 0.6 | 15 |
| 137 | Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. <i>Hepatology Communications</i> , 2022, 6, 1895-1909. | 2.0 | 15 |
| 138 | Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. <i>World Journal of Gastroenterology</i> , 2006, 12, 5078. | 1.4 | 14 |
| 139 | Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436. | 1.1 | 13 |
| 140 | Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <i>Phytotherapy Research</i> , 2021, 35, 6-19. | 2.8 | 13 |
| 141 | Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086. | 1.9 | 13 |
| 142 | Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 3855-3871. | 0.9 | 13 |
| 143 | Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. <i>Frontiers in Genetics</i> , 2012, 3, 253. | 1.1 | 12 |
| 144 | PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-63. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. <i>Frontiers in Pharmacology</i> , 2012, 3, 2. | 1.6 | 11 |
| 146 | The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410. | 1.9 | 10 |
| 147 | Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134. | 1.1 | 10 |
| 148 | Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2020, 41, 1523-1531. | 1.9 | 10 |
| 149 | Drug-Induced Liver Injury After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1167-1176. | 1.3 | 10 |
| 150 | Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021, 41, 2671-2680. | 1.9 | 9 |
| 151 | Acute Fulminant Hepatitis After Treatment With Rabeprazole and Terbinafine: Is Rabeprazole the Culprit?. <i>Archives of Internal Medicine</i> , 2002, 162, 360-361. | 4.3 | 9 |
| 152 | Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 282-283. | 0.1 | 9 |
| 153 | Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative. <i>Annals of Hepatology</i> , 2012, 11, 544-9. | 0.6 | 9 |
| 154 | Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-9. | 0.6 | 9 |
| 155 | Characterizing Drug-Induced Liver Injury With Autoimmune Features. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1844-1845. | 2.4 | 8 |
| 156 | Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury. <i>Journal of Pathology</i> , 2019, 247, 110-122. | 2.1 | 8 |
| 157 | Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. <i>Hepatology</i> , 2022, 76, 1259-1274. | 3.6 | 8 |
| 158 | Acute leukemia after infliximab therapy. <i>American Journal of Gastroenterology</i> , 2003, 98, 2577. | 0.2 | 7 |
| 159 | Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021, 95, 1475-1487. | 1.9 | 7 |
| 160 | Lansoprazole-Induced Hepatic Dysfunction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1731-1731. | 0.9 | 6 |
| 161 | Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 191-203. | 1.0 | 6 |
| 162 | Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. <i>Drug and Alcohol Dependence</i> , 1990, 26, 161-168. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Plasma Ribavirin Trough Concentrations During Treatment of Chronic Hepatitis C in Genotype-1 Patients. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 328-333. | 1.1 | 5 |
| 164 | Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1683-1685. | 2.4 | 4 |
| 165 | Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019, 14, e0225061. | 1.1 | 4 |
| 166 | Statins: Hepatic Disease and Hepatotoxicity Risk. <i>The Open Gastroenterology Journal</i> , 2008, 2, 18-23. | 0.1 | 4 |
| 167 | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55. | 1.4 | 4 |
| 168 | Portal hypertension and refractory ascites associated with multicentric Castleman's disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 697-702. | 1.1 | 3 |
| 169 | Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. <i>Digestive Diseases and Sciences</i> , 2002, 47, 304-308. | 1.1 | 3 |
| 170 | Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280. | 1.6 | 3 |
| 171 | A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385. | 0.2 | 3 |
| 172 | Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292. | 0.4 | 3 |
| 173 | Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391. | 3.6 | 3 |
| 174 | Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021, 95, 1793-1803. | 1.9 | 3 |
| 175 | Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021, 10, 5317. | 1.0 | 3 |
| 176 | Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. <i>Antiviral Therapy</i> , 2006, 11, 491-8. | 0.6 | 3 |
| 177 | Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022, 11, 897. | 2.2 | 3 |
| 178 | Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 477-496. | 0.1 | 2 |
| 179 | Landscape of Liver Injury From Herbal and Dietary Supplements in Europe, Latin America, and Asia. <i>Clinical Liver Disease</i> , 2019, 14, 49-50. | 1.0 | 2 |
| 180 | Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. <i>Gastroenterology & Hepatology</i> , 2022, 45, 342-349. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Corrigendum to "Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome" [J Hepatol 49 (2008) 107-114]. Journal of Hepatology, 2009, 50, 636. | 1.8 | 1 |
| 182 | S1873 The use of Liver Biopsy Evaluation in Determination of Autoimmune Hepatitis vs. Drug-Induced Liver Injury. Gastroenterology, 2010, 138, S-807. | 0.6 | 1 |
| 183 | Causality Assessment. , 2013, , 287-302. | | 1 |
| 184 | P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , . | | 1 |
| 185 | Reply:. Hepatology, 2009, 49, 1777-1779. | 3.6 | 0 |
| 186 | Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. Hepatology, 2010, 51, NA-NA. | 3.6 | 0 |
| 187 | Reply. Gastroenterology, 2014, 147, 1442. | 0.6 | 0 |
| 188 | Reply. Gastroenterology, 2015, 148, 452-453. | 0.6 | 0 |
| 189 | Reply letter to "Editorial: bodybuilders beware" Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473. | 1.9 | 0 |
| 190 | Herbal-induced liver injury: The price to pay for a healthier life?. Liver International, 2019, 39, 257-259. | 1.9 | 0 |